VANCOUVER, British Columbia–(BUSINESS WIRE)–SaNOtize Research and Development Corp. (“SaNOtize”), a Canadian anti-infective-focused therapeutics company, today announced the formation of its inaugural scientific advisory board...
Top investment opportunitiesStartup of the Week: SynergyMed, transforming surgery with 3D printing and visualizationWomen tech leaders in the spotlight at OurCrowd SummitOurCrowd in UAE:...
Horizons and Jerusalem-based OurCrowd lead US$24 million Series B funding round
Funding will go towards the expansion of a third-phase clinical trial of a nasal...
VANCOUVER, British Columbia–(BUSINESS WIRE)–SaNOtize Research & Development Corp., (“SaNOtize”), a Canadian anti-infective-focused therapeutics company, today announced an oversubscribed $24 million Series B funding to...
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of...
VANCOUVER, British Columbia & MUMBAI, July 13, 2022–SaNOtize Research & Development Corp., (“SaNOtize”), a Canadian anti-infective-focused therapeutics company, and Glenmark Pharmaceuticals Limited (“Glenmark”), a...
VANCOUVER, British Columbia–(BUSINESS WIRE)–SaNOtize Research and Development (“SaNOtize”) today announced results from a retrospective clinical study assessing the efficacy of nitric oxide releasing nasal...
SaNOtize CEO Dr. Gilly Regev visited Israel earlier this month as she inspected the increase in manufacturing production of her company’s antiviral nasal...
Startup of the Week: QuantLR, low-cost quantum encryption
Azerbaijan Investment Co. signs with OurCrowd
FDA clears RealView hologram for ‘sci-fi’ surgical planning
Nexa3D’s ‘Nexa Level’...
VANCOUVER, British Columbia & MUMBAI, India–(BUSINESS WIRE)–SaNOtize Research and Development Corp. and Indian company, Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today...